3SBio Inc. (1530.HK)
HKD 6.11
(-0.49%)
HKD 6.11
(-0.49%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.14 Billion CNY | -7.33% |
| 2022 | 2.31 Billion CNY | 1429.89% |
| 2021 | -174.38 Million CNY | 0.92% |
| 2020 | -176 Million CNY | -124.13% |
| 2019 | 729.28 Million CNY | -51.5% |
| 2018 | 1.5 Billion CNY | -25.19% |
| 2017 | 2 Billion CNY | -15.73% |
| 2016 | 2.38 Billion CNY | 366.94% |
| 2015 | -893.37 Million CNY | -274.67% |
| 2014 | 511.46 Million CNY | 290.7% |
| 2013 | -268.2 Million CNY | -67.4% |
| 2012 | -160.21 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 2.08 Billion CNY | 2.24% |
| 2024 Q1 | 2.08 Billion CNY | -3.12% |
| 2023 Q1 | 2.88 Billion CNY | 24.56% |
| 2023 FY | 2.14 Billion CNY | -7.33% |
| 2023 Q4 | 2.14 Billion CNY | 0.49% |
| 2023 Q3 | 2.13 Billion CNY | -26.27% |
| 2023 Q2 | 2.9 Billion CNY | 0.42% |
| 2022 Q4 | 2.31 Billion CNY | -1.51% |
| 2022 FY | 2.31 Billion CNY | 1429.89% |
| 2022 Q1 | 902.28 Million CNY | 617.42% |
| 2022 Q2 | 953.98 Million CNY | 5.73% |
| 2022 Q3 | 2.35 Billion CNY | 146.81% |
| 2021 FY | -174.38 Million CNY | 0.92% |
| 2021 Q2 | -273.57 Million CNY | 3.53% |
| 2021 Q1 | -283.57 Million CNY | -61.11% |
| 2021 Q3 | -249.76 Million CNY | 8.7% |
| 2021 Q4 | -174.38 Million CNY | 30.18% |
| 2020 Q1 | 614.38 Million CNY | -15.75% |
| 2020 Q2 | 622.55 Million CNY | 1.33% |
| 2020 Q3 | -183.72 Million CNY | -129.51% |
| 2020 Q4 | -176 Million CNY | 4.2% |
| 2020 FY | -176 Million CNY | -124.13% |
| 2019 FY | 729.28 Million CNY | -51.5% |
| 2019 Q1 | 2.3 Billion CNY | 53.26% |
| 2019 Q4 | 729.28 Million CNY | -8.26% |
| 2019 Q3 | 794.96 Million CNY | -64.43% |
| 2019 Q2 | 2.23 Billion CNY | -3.01% |
| 2018 Q1 | 1.74 Billion CNY | -13.41% |
| 2018 Q4 | 1.5 Billion CNY | -4.4% |
| 2018 Q3 | 1.57 Billion CNY | -6.03% |
| 2018 Q2 | 1.67 Billion CNY | -3.83% |
| 2018 FY | 1.5 Billion CNY | -25.19% |
| 2017 Q2 | 1.9 Billion CNY | -3.48% |
| 2017 Q3 | 2.07 Billion CNY | 8.72% |
| 2017 Q4 | 2 Billion CNY | -3.14% |
| 2017 FY | 2 Billion CNY | -15.73% |
| 2017 Q1 | 1.97 Billion CNY | -17.08% |
| 2016 Q1 | 2.77 Billion CNY | 410.71% |
| 2016 FY | 2.38 Billion CNY | 366.94% |
| 2016 Q4 | 2.38 Billion CNY | -4.27% |
| 2016 Q3 | 2.49 Billion CNY | -10.4% |
| 2016 Q2 | 2.78 Billion CNY | 0.16% |
| 2015 Q3 | -894.39 Million CNY | 71.71% |
| 2015 Q2 | -3.16 Billion CNY | 0.05% |
| 2015 Q1 | -3.16 Billion CNY | -718.46% |
| 2015 FY | -893.37 Million CNY | -274.67% |
| 2015 Q4 | -893.37 Million CNY | 0.11% |
| 2014 FY | 511.46 Million CNY | 290.7% |
| 2014 Q4 | 511.46 Million CNY | 0.0% |
| 2014 Q1 | 527.85 Million CNY | 296.81% |
| 2013 FY | -268.2 Million CNY | -67.4% |
| 2013 Q4 | -268.2 Million CNY | 0.0% |
| 2012 Q4 | -450.55 Million CNY | -26.99% |
| 2012 FY | -160.21 Million CNY | 0.0% |
| 2012 Q3 | -354.8 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | -76.36 Million HKD | 2914.086% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.26 Billion HKD | 59.195% |